Cellectar Biosciences, Inc.
CLRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001279704
No open-market purchases or sales by Cellectar Biosciences, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $9.08M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Cellectar Biosciences, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 32 | 33 | +1 |
| Shares | 6.82M | 6.65M | −167.8K (−2.5%) |
| Value | $4.69M | $3.61M | −$1.08M (−23.1%) |
New holders (4)
Institutions that held Cellectar Biosciences, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 68,990 | $28.0K | 0.00% |
| Virtu Financial LLC | 15,441 | $6.00K | 0.00% |
| Jane Street Group, LLC | 13,543 | $5.00K | 0.00% |
| Bank of America Corp | 1,500 | $1.00K | 0.00% |
Sold out (3)
Institutions that held Cellectar Biosciences, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Monticello Wealth Management, LLC | 120,000 | $83.0K |
| Sterneck Capital Management, LLC | 30,000 | $21.0K |
| Two Sigma Advisers, LP | 10,700 | $7.00K |